Pirmenol hydrochloride

Research use only, not for human use.

An orally effective, long-acting antiarrhythmic agent that interacts with cardiac muscarinic receptors.

An orally effective, long-acting antiarrhythmic agent that interacts with cardiac muscarinic receptors.Heart Arrhythmia Approved.

Pirmenol (1 μM) hydrochloride inhibits the IK.ACh induced by carbachol or intracellular loading of GTPg S in in atrial cells.Pirmenol (5 μM) hydrochloride depresses the early part of the plateau and lengthened the final repolarization of the action potentials in ventricular myocytes.Pirmenol (1 μM) hydrochloride prolongs the action potential duration at 90% repolarization in atrial muscles and Purkinje fibers.

Pirmenol (2.5 and 5 mg/kg, p.o.) hydrochloride is effective against the arrhythmias in conscious, coronary artery ligated dogs.Pirmenol (rats) hydrochloride shows LD50s of 359.9 mg/kg (p.o), 23.6 mg/kg (i.v.).Pirmenol (mice) hydrochloride shows LD50s of 215.5 mg/kg (p.o), 20.8 mg/kg (i.v.). Animal Model:Conscious, coronary artery ligated dogs Dosage:Oral administration (p.o.)Administration:2.5 and 5 mg/kg Result:Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin.

Cl-845 | (±)-Pirmenol hydrochloride

GPCR/G Protein

mAChR

mAChR

Cardiovascular Disease

Heart Arrhythmia

61477-94-9

374.9473

C22H31ClN2O

>98% (HPLC)

DMSO: ≥ 28 mg/mL

CC1CCCC(N1CCCC(C2=CC=CC=C2)(C3=CC=CC=N3)O)C.Cl

2-Pyridinemethanol, α-[3-[(2R,6S)-2,6-dimethyl-1-piperidinyl]propyl]-α-phenyl-, hydrochloride (1:1), rel-

(-20℃)

With Ice Pack

≥ 2 years